Orgenesis Inc (ORGS) - Net Assets
Based on the latest financial reports, Orgenesis Inc (ORGS) has net assets worth $-23.93 Million USD as of September 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($29.69 Million) and total liabilities ($53.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Orgenesis Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-23.93 Million |
| % of Total Assets | -80.6% |
| Annual Growth Rate | N/A |
| 5-Year Change | -445.23% |
| 10-Year Change | N/A |
| Growth Volatility | 249.64 |
Orgenesis Inc - Net Assets Trend (2008–2023)
This chart illustrates how Orgenesis Inc's net assets have evolved over time, based on quarterly financial data. Also explore ORGS asset base for the complete picture of this company's asset base.
Annual Net Assets for Orgenesis Inc (2008–2023)
The table below shows the annual net assets of Orgenesis Inc from 2008 to 2023. For live valuation and market cap data, see Orgenesis Inc (ORGS) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-20.98 Million | -135.40% |
| 2022-12-31 | $59.27 Million | +53.44% |
| 2021-12-31 | $38.63 Million | -26.74% |
| 2020-12-31 | $52.73 Million | +767.52% |
| 2019-12-31 | $6.08 Million | -78.78% |
| 2018-12-31 | $28.65 Million | 0.00% |
| 2018-11-30 | $28.65 Million | +102.85% |
| 2017-12-31 | $14.12 Million | +33.51% |
| 2016-12-31 | $10.58 Million | +264.25% |
| 2015-12-31 | $-6.44 Million | -116.16% |
| 2014-12-31 | $-2.98 Million | -46.44% |
| 2013-12-31 | $-2.03 Million | -625.14% |
| 2012-12-31 | $-280.56K | -239.36% |
| 2011-12-31 | $-82.67K | -701.02% |
| 2010-12-31 | $-10.32K | -139.92% |
| 2009-12-31 | $25.85K | -49.80% |
| 2008-12-31 | $51.50K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Orgenesis Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17661850000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | % |
| Other Comprehensive Income | $65.00K | % |
| Other Components | $155.57 Million | % |
| Total Equity | $-20.98 Million | 100.00% |
Orgenesis Inc Competitors by Market Cap
The table below lists competitors of Orgenesis Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Saxlund Group AB
ST:SAXG
|
$9.84 Million |
|
Fanhua Inc
F:4CIA
|
$9.84 Million |
|
bioAffinity Technologies, Inc.
NASDAQ:BIAF
|
$9.85 Million |
|
Academies Australasia Group Ltd
AU:AKG
|
$9.85 Million |
|
Vigor Kobo Co Ltd
TWO:2733
|
$9.81 Million |
|
Total Transport Systems Limited
NSE:TOTAL
|
$9.81 Million |
|
Prg Holdings Bhd
KLSE:7168
|
$9.80 Million |
|
Cenntro Electric Group Ltd
NASDAQ:CENN
|
$9.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Orgenesis Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 27,561,000 to -20,983,000, a change of -48,544,000 (-176.1%).
- Net loss of 55,361,000 reduced equity.
- New share issuances of 5,516,000 increased equity.
- Other comprehensive income increased equity by 335,000.
- Other factors increased equity by 966,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-55.36 Million | -263.84% |
| Share Issuances | $5.52 Million | +26.29% |
| Other Comprehensive Income | $335.00K | +1.6% |
| Other Changes | $966.00K | +4.6% |
| Total Change | $- | -176.13% |
Book Value vs Market Value Analysis
This analysis compares Orgenesis Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $0.01 | $1.95 | x |
| 2009-12-31 | $0.00 | $1.95 | x |
| 2010-12-31 | $0.00 | $1.95 | x |
| 2011-12-31 | $-0.01 | $1.95 | x |
| 2012-12-31 | $-0.06 | $1.95 | x |
| 2013-12-31 | $-0.48 | $1.95 | x |
| 2014-12-31 | $-0.65 | $1.95 | x |
| 2015-12-31 | $-1.36 | $1.95 | x |
| 2016-12-31 | $1.24 | $1.95 | x |
| 2017-12-31 | $1.45 | $1.95 | x |
| 2018-11-30 | $2.12 | $1.95 | x |
| 2018-12-31 | $2.12 | $1.95 | x |
| 2019-12-31 | $0.34 | $1.95 | x |
| 2020-12-31 | $2.47 | $1.95 | x |
| 2021-12-31 | $1.59 | $1.95 | x |
| 2022-12-31 | $1.10 | $1.95 | x |
| 2023-12-31 | $-0.72 | $1.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Orgenesis Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10445.47%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-68.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -6.80% | 0.00% | 0.00x | 1.07x | $-8.65K |
| 2009 | -99.21% | 0.00% | 0.00x | 1.23x | $-28.23K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-35.14K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-64.08K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.97 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.34 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.21 Million |
| 2015 | 0.00% | -150.00% | 0.08x | 0.00x | $-3.82 Million |
| 2016 | -86.92% | -143.72% | 0.19x | 3.17x | $-10.25 Million |
| 2017 | -87.57% | -122.58% | 0.25x | 2.82x | $-13.78 Million |
| 2018 | -64.52% | -98.05% | 0.25x | 2.66x | $-21.13 Million |
| 2018 | -64.52% | -98.05% | 0.25x | 2.66x | $-21.13 Million |
| 2019 | -475.46% | -78.30% | 0.36x | 16.89x | $-26.59 Million |
| 2020 | -180.92% | -1243.17% | 0.10x | 1.48x | $-100.38 Million |
| 2021 | -46.92% | -50.87% | 0.59x | 1.55x | $-21.91 Million |
| 2022 | -44.15% | -33.78% | 0.40x | 3.30x | $-14.93 Million |
| 2023 | 0.00% | -10445.47% | 0.04x | 0.00x | $-53.26 Million |
Industry Comparison
This section compares Orgenesis Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Orgenesis Inc (ORGS) | $-23.93 Million | -6.80% | N/A | $9.83 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Orgenesis Inc
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of res… Read more